Industrial Pharmacy Advisory Group (IPAG)

Experts in Industrial Pharmacy

RPS Industrial Pharmacy Advisory Group (IPAG) provides a source of expertise on issues of pharmacy practice which impact on patients, the public, and the profession.

IPAG is a consultative group to the Boards of the RPS, acting as a source of expertise and advice, and providing evidenced-based leadership and opinion to inform RPS policy decisions and advice to government and other organisations.

The main aim of IPAG is to provide leadership in practice, identify and track the changing healthcare environment, advise on the implications for the industrial sector and the RPS and also highlight the changing professional needs and competencies of its members.

Read the Terms of Reference for the Industrial Pharmacy Advisory Group (IPAG).


  • Sunayana Shah (Chair)
  • Neel Bhatt
  • Ciara O'Brien
  • Jeremy Clarke
  • Vito Constanza
  • Diar Fattah
  • Sarah Goffin
  • Hari Harrar
  • Pervaise Khan
  • Sue Kilby
  • Yetunde Kolade
  • Jenifer Mains
  • Stephen Makin
  • Ricardo Martinez-Moreno-Davila
  • Jane Nicholson
  • Mine Orlu
  • Marco Picone
  • Kendall Pitt
  • Robert Smith
  • Rebecca Stanbrook
  • Pratik Thakkar

CCS webinar_20220923-page-001637981363188467102

EIPG Webinar

Implementation of Contamination Control Strategy (CCS)
Using the ECA Template

With Walid Al Azab

Click the flyer to download a copy.

Friday 21 October 2022, 1600 CEST (1500 BST)


The EIPG UK Country Report 2021

Read the latest report to the European Industrial Pharmacists' Group here

The EIPG newsletter

Read the official newsletter of the European Industrial Pharmacists' Group.

  • Read the July 2022 newsletter
    In this July issue, you'll find articles on the EMA's industry stakeholders' group (or ISG), ICMRA - two pilot programmes to optimise regulatory assessment and inspections, the new European innovation agenda, and Trends in Drug delivery and Formulation.
  • Read the June 2022 newsletter
    In this June issue, you'll find articles on IVD regulation in force & new MDCG guidelines (CTR –UDI), The Digital Application Dataset Integration (DADI) user interface, EIC: challenges for the governance & opportunities for innovation, The Data Governance Act & the protection of personal data (CTIS) and Consultation on draft Q&As on remote certification of batches.
  • Read the May 2022 newsletter
    In this May issue, you'll find articles on Key issues in technical due diligences, Joint implementation plan for the IVDR regulation, Draft topics for the first IHI calls for proposals, The PIC/S Annual Report 2021 and Implications and Opportunities of ICHQ2(R2) and ICHQ14
  • Read the April 2022 newsletter
    In this April issue, you'll find articles on Trends in the development of new dosage forms, A new joint work plan to 2023 for EMA and EUnetHTA 21, IPI - a new international procurement instrument at the EU level, EDQM: the RealTime Remote Inspections (RTEMIS) scheme for remote inspections, and Revision of the PIC/S GMP Guide: Annex 13 and Annex 16
  • Read the March 2022 newsletter
    In this March issue, you'll find articles on FAT and SAT, a critical step for the introduction of new equipment, The new Annex 21 to GMPs, The main contributions to the consultation on the revision of the pharmaceutical legislation, The Made in Europe Partnership for manufacturing and Academic Research in Industrial Pharmacy field.
  • Read the February 2022 newsletter
    In this February issue, you'll find articles on Investing in formulation as success’ factor, Revision of the CDMh’s Q&As document on nitrosamine impurities, A record year for biotech investments in the UK a year after the Brexit, Faculty of Pharmacy is once again a part of Masaryk University and Continuous Manufacturing of Pharmaceuticals: Higher Quality, Greater Flexibility.
  • Read the January 2022 newsletter
    In this January issue, you'll find articles on EU Medicines Regulatory Network Data Standardisation Strategy, EMA’s Q&A on the integration of EudraGMDP and OMS, ACT EU: the EU’s vision for the future of clinical trials and a Reflection paper published by ICMRA on remote inspections.